Human γδ T cell sensing of AMPK-dependent metabolic tumor reprogramming through TCR recognition of EphA2.


Journal

Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624

Informations de publication

Date de publication:
30 07 2021
Historique:
received: 19 01 2020
accepted: 01 07 2021
entrez: 31 7 2021
pubmed: 1 8 2021
medline: 11 3 2022
Statut: ppublish

Résumé

Human γδ T cells contribute to tissue homeostasis and participate in epithelial stress surveillance through mechanisms that are not well understood. Here, we identified ephrin type-A receptor 2 (EphA2) as a stress antigen recognized by a human Vγ9Vδ1 TCR. EphA2 is recognized coordinately by ephrin A to enable γδ TCR activation. We identified a putative TCR binding site on the ligand-binding domain of EphA2 that was distinct from the ephrin A binding site. Expression of EphA2 was up-regulated upon AMP-activated protein kinase (AMPK)-dependent metabolic reprogramming of cancer cells, and coexpression of EphA2 and active AMPK in tumors was associated with higher CD3 T cell infiltration in human colorectal cancer tissue. These results highlight the potential of the human γδ TCR to cooperate with a co-receptor to recognize non-MHC-encoded proteins as signals of cellular dysregulation, potentially allowing γδ T cells to sense metabolic energy changes associated with either viral infection or cancer.

Identifiants

pubmed: 34330813
pii: 6/61/eaba9010
doi: 10.1126/sciimmunol.aba9010
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antigens 0
EPHA2 protein, human 0
Receptors, Antigen, T-Cell, gamma-delta 0
Receptor, EphA2 EC 2.7.10.1
AMP-Activated Protein Kinases EC 2.7.11.31

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
ID : 099266/Z/12/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 221725/Z/20/Z
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Christelle Harly (C)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France.

Stephen Paul Joyce (SP)

Cancer Immunology and Immunotherapy Centre, Cancer Research UK Birmingham Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.

Charlotte Domblides (C)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France.

Thomas Bachelet (T)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France.

Vincent Pitard (V)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France.
Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Bordeaux University CNRS UMS3427, INSERM US05, Flow Cytometry Facility, TransBioMed Core, 33000 Bordeaux, France.

Charlotte Mannat (C)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France.

Angela Pappalardo (A)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France.

Lionel Couzi (L)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France.
Renal Transplantation Department, Bordeaux University Hospital, 33076 Bordeaux, France.

Sonia Netzer (S)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France.
Equipe Labellisée Ligue Contre le Cancer, Paris, France.

Layal Massara (L)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France.
Equipe Labellisée Ligue Contre le Cancer, Paris, France.

Emilie Obre (E)

Cellomet, Centre de Génomique Fonctionnelle Bordeaux, University of Bordeaux, 33076 Bordeaux, France.

Omar Hawchar (O)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France.

Lydia Lartigue (L)

INSERM U1218 ACTION, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France.

Stéphane Claverol (S)

Centre de Génomique Fonctionnelle Bordeaux, University of Bordeaux, 33000 Bordeaux, France.

Carla Cano (C)

ImCheck Therapeutics, 13009 Marseille, France.

Jean-François Moreau (JF)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France.
Immunology and Immunogenetics Laboratory, Bordeaux University Hospital, F-33000 Bordeaux, France.

Isabelle Mahouche (I)

INSERM, U1218 ACTION, F-33000 Bordeaux, France.

Isabelle Soubeyran (I)

INSERM, U1218 ACTION, F-33000 Bordeaux, France.

Rodrigue Rossignol (R)

Cellomet, Centre de Génomique Fonctionnelle Bordeaux, University of Bordeaux, 33076 Bordeaux, France.
INSERM U1211, Rare diseases, Genetics and Metabolism, University of Bordeaux, Bordeaux, France.

Benoit Viollet (B)

Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Sorbonne Paris cité, Paris, France.

Carrie R Willcox (CR)

Cancer Immunology and Immunotherapy Centre, Cancer Research UK Birmingham Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.

Fiyaz Mohammed (F)

Cancer Immunology and Immunotherapy Centre, Cancer Research UK Birmingham Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.

Benjamin E Willcox (BE)

Cancer Immunology and Immunotherapy Centre, Cancer Research UK Birmingham Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK. jdechanet@immuconcept.org benfaustin@gmail.com b.willcox@bham.ac.uk.

Benjamin Faustin (B)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France. jdechanet@immuconcept.org benfaustin@gmail.com b.willcox@bham.ac.uk.
Immunology Discovery, Janssen Research & Development, San Diego, CA, USA.

Julie Déchanet-Merville (J)

Bordeaux University, CNRS, ImmunoConcept, UMR 5164, 33000 Bordeaux, France. jdechanet@immuconcept.org benfaustin@gmail.com b.willcox@bham.ac.uk.
Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Bordeaux University CNRS UMS3427, INSERM US05, Flow Cytometry Facility, TransBioMed Core, 33000 Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH